ElevateBio Funding & Investors
ElevateBio is an operator of a portfolio of cell and gene therapy companies intended to develop, manufacture, and commercialize life-transforming medicines. The company creates a portfolio through partnerships with the world's innovative scientists and inventors as well as it created a centralized facility that integrates all the elements that translate cell and gene therapy R&D into commercially viable therapies quickly and efficiently, enabling patients to get medical products to treat severe diseases. Vikas Sinha, Mitchell Finer, and David Hallal co-founded ElevateBio in Cambridge, Massachusetts in 2017.
elevate.bioTotal Amount Raised: $1,260,000,000
ElevateBio Funding Rounds
Series D
$401,000,000
Series D Investors
Novo NordiskEcoR1 CapitalWoodline PartnersSoftBank Investment AdvisersEDBIMPM CapitalF2 VenturesVertex VenturesLee Family OfficeFidelity Management and Research CompanySamsara BioCapitalSurveyor CapitalRedmile GroupEmerson CollectiveITOCHUInvus GroupMatrix Capital ManagementAngel
$14,000,000
Angel Investors
Qiming Venture PartnersSeries C
$525,000,000
Series C Investors
EcoR1 CapitalSoftBank Investment AdvisersEDBIMPM CapitalF2 VenturesVertex VenturesFidelity Management and Research CompanySamsara BioCapitalSurveyor CapitalRedmile GroupITOCHUEmerson CollectiveInvus GroupMatrix Capital ManagementSeries B
$170,000,000
Series B Investors
Redmile GroupEcoR1 CapitalInvus GroupEDBIMPM CapitalF2 VenturesVertex VenturesSamsara BioCapitalSurveyor CapitalSeries A
$150,000,000
Series A Investors
Redmile GroupEcoR1 CapitalUBS Oncology Impact FundSamsara BioCapital
Funding info provided by Diffbot.